VC Funding Dips In Q3, But 2024 Already Bests Full-Year 2023

Mega-Round Surge Boosts Overall Totals

Data from Evaluate show that biopharma venture capital investment fell from $7.95bn in Q2 to $6.59bn in Q3, but both outpaced every quarter in 2023 as the financial market recovery continues.

Screen display representing venture capital investment
VC investment dipped in Q3, but is up for the year • Source: Shutterstock

Venture capital investment in biopharmaceutical companies dropped by more than $1bn from the second to the third quarter, according to the latest data from Evaluate, but the amount of VC dollars invested in drug developers through the first nine months of 2024 is higher than the total for all of 2023.

Biopharma capital markets watchers have noted throughout this year that a recovery is under way, with fundraising conditions improving relative...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

Venture Funding Plummets In Q2 As Mega-Rounds Falter

 
• By 

Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.

Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates

 
• By 

Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

More from Business

Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates

 
• By 

Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By 

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.